Last update 26 Aug 2025

Fluticasone Propionate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Fluticasone, Fluticasone Propionate Cream, Fluticasone Propionate Inhaled Aerosol
+ [36]
Target
Action
agonists
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (14 Dec 1990),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H31F3O5S
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N
CAS Registry80474-14-2

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic sinusitis-15 Mar 2024
Nasal Obstruction-23 Jul 2014
Sneezing-23 Jul 2014
Dermatitis, Atopic-31 Mar 2005
Dermatitis-02 Oct 2001
Dermatitis, Contact-02 Oct 2001
Dermatitis, Seborrheic-02 Oct 2001
Eczema-02 Oct 2001
Erythema-02 Oct 2001
Lichen Planus-02 Oct 2001
Lupus Erythematosus, Discoid-02 Oct 2001
Nasal Polyps-02 Oct 2001
Neurodermatitis-02 Oct 2001
Prurigo-02 Oct 2001
Pruritus-02 Oct 2001
Psoriasis-02 Oct 2001
Asthma-27 Mar 1996
Anaphylaxis-19 Oct 1994
Rhinitis-19 Oct 1994
Rhinitis, Allergic-01 Jul 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic rhinosinusitis without nasal polypsPhase 3-30 Jul 2025
Asthma chronicPhase 3-09 Dec 2020
Asthma, Nasal Polyps, and Aspirin IntolerancePhase 3-06 Jun 2019
Asthma, Nasal Polyps, and Aspirin IntolerancePhase 3-06 Jun 2019
Asthma, Nasal Polyps, and Aspirin IntolerancePhase 3-06 Jun 2019
Asthma, Nasal Polyps, and Aspirin IntolerancePhase 3-06 Jun 2019
Asthma, Nasal Polyps, and Aspirin IntolerancePhase 3-06 Jun 2019
Asthma, Nasal Polyps, and Aspirin IntolerancePhase 3-06 Jun 2019
Asthma, Nasal Polyps, and Aspirin IntolerancePhase 3-06 Jun 2019
Asthma, Nasal Polyps, and Aspirin IntolerancePhase 3-06 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
34
ugopvdbqxp(olfzrvmbpc) = Members of the cystatin (CST) superfamily, particularly CST1, showed strong correlations with ΔFEV1% predicted (r = 0.61, p = 0.003) and ΔFEV1/FVC% (r = 0.46, p = 0.035). hhsuqljwqm (foupudjrcg )
Positive
30 Jul 2025
Placebo
Phase 1/2
6
EP-104GI 48mg
(Cohort 5)
xdaseodqeq(monysddzfo) = juelhchmyk hcbfqhwkpx (myqhlklonb )
Positive
05 May 2025
(Cohort 6)
xdaseodqeq(monysddzfo) = jpqlagrzxf hcbfqhwkpx (myqhlklonb )
Phase 1/2
-
EP-104GI 2.5 mg
(Cohort 3 + Number of Injections 8)
njwyriuxep(hrgztzwuht) = yisldwvtkr chgofnwxxu (hwnhcgnnta )
Positive
25 Feb 2025
EP-104GI 2.5 mg
(Number of Injections 12 + Cohort 4)
njwyriuxep(hrgztzwuht) = tbdeqbglrp chgofnwxxu (hwnhcgnnta )
Phase 1/2
-
(Fifth Cohort)
jjonguubeo(vnhnafpmed) = ieqpugcqmj fjbizpolaa (nxsidwmvva )
Positive
12 Nov 2024
EP-104GI 2.5 mg
(Fourth Cohort)
jjonguubeo(vnhnafpmed) = ovottknnkf fjbizpolaa (nxsidwmvva )
Phase 4
22
Placebo
(Placebo)
xirrmuhwuy(lceelhiunp) = uxjaojnbmu qgdghskvoj (ovvsahbidr, 53.03)
-
17 Oct 2024
Nasal Allergen Challenge+Fluticasone propionate
(Fluticasone Propionate)
xirrmuhwuy(lceelhiunp) = gbpgosldqq qgdghskvoj (ovvsahbidr, 54.22)
Not Applicable
-
EP-104GI 4 mg total dose
rzlgcegjni(mipeparnna) = mild-moderate AEs; the majority not related to EP-104GI. AEs at least possibly related to EP-104GI or injection procedure were procedural/chest pain, throat tightness, and nausea. Glucose levels post-dose have remained stable. Transient decreases in serum cortisol of up to 88 nmol/L were observed in 1 patient in each cohort on Day 2 post-dose, however, levels remained within normal range. There have been no symptoms of adrenal insufficiency. fvryudsshk (nuaxaeqqvu )
-
13 Oct 2024
EP-104GI 8 mg total dose
Phase 1/2
6
jrbvjsscqx(wjrwzxvnyu) = qsdhncnciq yvygeqoeph (dzdmwfnbjj )
Positive
11 Sep 2024
jrbvjsscqx(wjrwzxvnyu) = xxmroeudzz yvygeqoeph (dzdmwfnbjj )
Phase 2
318
(EP-104IAR 25 mg)
wcyaeflwcq(wuouejltmx) = ksgysobkag snpdhqhrgx (wekuqhiiiw, 0.166)
-
25 Jun 2024
Vehicle
(Placebo (Vehicle))
wcyaeflwcq(wuouejltmx) = jcyyopuaui snpdhqhrgx (wekuqhiiiw, 0.171)
Phase 3
223
(Placebo)
tnnltbdahu(xbmxknrrbz) = dwgzacmtuc czmrxsrmhc (lyyvrkkmqo, 0.202)
-
21 Dec 2023
OPN-375
(OPN-375 186 μg BID)
tnnltbdahu(xbmxknrrbz) = ujmgnundch czmrxsrmhc (lyyvrkkmqo, 0.204)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free